Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 2/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.49 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674276 | 0.89 | GBA1 (0.71) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL2027845 | 0.89 | GBA1 (0.71) | GBA1CCR3PRMT3CARM1PRMT6 | |
| Ammonia Solution, Strong SCHEMBL1432566 | 0.86 | GBA1 (0.68) | GBA1CCR3PRMT3CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL4797146 | 0.84 | GBA1 (0.65) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL8701 | 0.79 | GBA1 (0.65) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL316482 | 0.79 | GBA1 (0.65) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL8595149 | 0.78 | GBA1 (0.59) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL8414688 | 0.78 | GBA1 (0.59) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL5525779 | 0.78 | GBA1 (0.59) | GBA1CCR3PRMT3CARM1PRMT6 | |
| SCHEMBL10523879 | 0.78 | GBA1 (0.59) | GBA1CCR3PRMT3CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1014 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | claimed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | claimed |
| US-12043573-B2 | Adhesion promoters and gel-modifiers for olefin metathesis compositions | MATERIA, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3386936-B1 | OLEFIN METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-118317986-A | Hydrophobically modified and hydrophilically modified maleated natural oils, salts, compositions and methods of use | 埃斯普投资有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118302488-A | Hydrophobically modified and hydrophilically modified maleated natural oils and compositions thereof | 埃斯普投资有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113423549-B | Coating composition | 马特里亚公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118235086-A | Radiation-sensitive composition comprising a combination of metals or metalloid compounds | 埃斯普投资有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-3016991-B1 | LIQUID MOLDING COMPOSITIONS | MATERIA INC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240174688-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-30 | — | — | US | disclosed |
| CN-118059093-A | Inhibitors of short chain dehydrogenase activity for the treatment of fibrosis | 卡斯西部储备大学 | 2024-05-24 | — | — | CN | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1173193-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | The Trustees of Princeton University (US) | 2002-01-23 | — | — | EP | disclosed |
| CN-1071334-C | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2001-09-19 | — | — | CN | disclosed |
| WO-2000059528-A1 | DESLEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHODS OF MAKING SAME | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| CN-1119649-A | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 1996-04-03 | — | — | CN | disclosed |
| US-4818748-A | HYPOTENSIVE AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| EP-0236874-A2 | Renin inhibitors, their production and use, as well as derivatives of amino acids and amino aldehydes | BAYER AG (DE) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174688-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | GBA1 946/4885CCR3 4569/4885PRMT3 2786/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | GBA1 2232/4885CCR3 151/4885PRMT3 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.